{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:55:39Z","timestamp":1787504139870,"version":"build-2736575974"},"reference-count":63,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.det.2024.09.001","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T06:51:48Z","timestamp":1729061508000},"page":"27-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Innovation in Alopecia Areata"],"prefix":"10.1016","volume":"43","author":[{"given":"Luiza","family":"Kalil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.det.2024.09.001_bib1","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jaad.2019.08.032","article-title":"Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis","volume":"82","author":"Lee","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.09.001_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2017.04.1141","article-title":"Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis","volume":"78","author":"Strazzulla","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.09.001_bib3","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s40257-023-00808-1","article-title":"Alopecia areata: current treatments and new directions","volume":"24","author":"Dahabreh","year":"2023","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.09.001_bib4","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","article-title":"Alopecia areata investigational assessment guidelines--Part II. National alopecia areata foundation","volume":"51","author":"Olsen","year":"2004","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.09.001_bib5","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bjd.18883","article-title":"The alopecia areata investigator global assessment scale: a measure for evaluating clinically meaningful success in clinical trials","volume":"183","author":"Wyrwich","year":"2020","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.09.001_bib6","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jaad.2006.05.008","article-title":"Alopecia areata: a long term follow-up study of 191 patients","volume":"55","author":"Tosti","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.09.001_bib7","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2023.0002","article-title":"Trends in prevalence and incidence of alopecia areata, alopecia totalis, and alopecia universalis among adults and children in a US employer-sponsored insured population","volume":"159","author":"Mostaghimi","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.09.001_bib8","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/j.1365-2133.2012.10955.x","article-title":"British Association of Dermatologists' guidelines for the management of alopecia areata 2012","volume":"166","author":"Messenger","year":"2012","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.09.001_bib9","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.jaad.2020.09.028","article-title":"The Alopecia Areata Consensus of Experts (ACE) study part II: results of an international expert opinion on diagnosis and laboratory evaluation for alopecia areata","volume":"84","author":"Meah","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.09.001_bib10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000501940","article-title":"Monotherapy for alopecia areata: a systematic review and network meta-analysis","volume":"5","author":"Gupta","year":"2019","journal-title":"Skin Appendage Disord"},{"key":"10.1016\/j.det.2024.09.001_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1243556","article-title":"Inhibition of T-cell activity in alopecia areata: recent developments and new directions","volume":"14","author":"Passeron","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.det.2024.09.001_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.955035","article-title":"An overview of JAK\/STAT pathways and JAK inhibition in alopecia areata","volume":"13","author":"Lensing","year":"2022","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.det.2024.09.001_bib13","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1038\/jid.2014.260","article-title":"Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis","volume":"134","author":"Craiglow","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"issue":"15","key":"10.1016\/j.det.2024.09.001_bib14","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Kennedy","year":"2016","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.det.2024.09.001_bib15","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jdcr.2020.02.007","article-title":"Successful treatment of alopecia totalis with ruxolitinib in a preadolescent patient","volume":"6","author":"Peterson","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"15","key":"10.1016\/j.det.2024.09.001_bib16","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight"},{"issue":"18","key":"10.1016\/j.det.2024.09.001_bib17","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.det.2024.09.001_bib18","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40257-023-00764-w","article-title":"Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2)","volume":"24","author":"Kwon","year":"2023","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.09.001_bib19","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/bjd\/ljac059","article-title":"Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials","volume":"188","author":"King","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2024.09.001_bib20","unstructured":"A study of baricitinib (LY3009104) in children from 6 years to less than 18 years of age with alopecia areata (BRAVE-AA-PEDS). clinicaltrials.gov [Internet]. Bethesda (MD): National library of medicine. Available at: clinicaltrials.gov\/study\/NCT05723198. (Accessed 3 October 2024)."},{"issue":"10387","key":"10.1016\/j.det.2024.09.001_bib21","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","article-title":"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial","volume":"401","author":"King","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.det.2024.09.001_bib22","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40257-024-00846-3","article-title":"Integrated safety analysis of ritlecitinib, an oral JAK3\/TEC family kinase inhibitor, for the treatment of alopecia areata from the ALLEGRO clinical trial program","volume":"25","author":"King","year":"2024","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.09.001_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2023.07.177","article-title":"Efficacy of the Oral JAK1\/JAK2 inhibitor CTP-543 (Deuruxolitinib) in adult patients with moderate to severe alopecia areata: results from the multinational double-blind, placebo-controlled THRIVE-AA1 phase 3 trial","volume":"89","author":"Senna","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2024.09.001_bib24","unstructured":"Study to evaluate the efficacy and safety of CTP-543 in adults with moderate to severe alopecia areata (THRIVE-AA2). clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine. Available at: clinicaltrials.gov\/study\/NCT03137381. (Accessed 3 October 2024)."},{"key":"10.1016\/j.det.2024.09.001_bib25","article-title":"Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the Phase 3 randomized, controlled trial (THRIVE-AA1)","volume":"23","author":"King","year":"2024","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.09.001_bib26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaad.2022.12.056","article-title":"Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: a retrospective cohort study","volume":"89","author":"Flora","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.09.001_bib27","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jaad.2023.05.001","article-title":"Beneficial effects of upadacitinib on alopecia areata associated with atopic dermatitis: a multicenter retrospective study","volume":"89","author":"Chiricozzi","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2024.09.001_bib28","unstructured":"A study to evaluate the safety and effectiveness of upadacitinib tablets in adult and adolescent participants with severe alopecia areata (Up-AA). clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine. Available at: clinicaltrials.gov\/study\/NCT06012240. (Accessed 3 October 2024)."},{"issue":"5","key":"10.1016\/j.det.2024.09.001_bib29","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jaad.2023.02.063","article-title":"A\u00a0randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata","volume":"89","author":"Zhou","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2024.09.001_bib30","unstructured":"Evaluate the efficacy and safety of SHR0302 in adult patients with severe alopecia areata. clinicaltrials.gov [Internet]. Bethesda (MD): National library of medicine. Available at: clinicaltrials.gov\/study\/NTC05470413. (Accessed 3 October 2024)."},{"issue":"1","key":"10.1016\/j.det.2024.09.001_bib31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2024.09.001_bib32","unstructured":"A study to evaluate efficacy and safety of deucravacitinib in participants with alopecia areata. clinicaltrials.gov [Internet]. Bethesda (MD): National library of medicine. Available at: clinicaltrials.gov\/study\/NCT05556265. (Accessed 3 October 2024)."},{"issue":"24","key":"10.1016\/j.det.2024.09.001_bib33","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.det.2024.09.001_bib34","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jdcr.2017.11.020","article-title":"Alopecia areata after dupilumab for atopic dermatitis","volume":"4","author":"Mitchell","year":"2018","journal-title":"JAAD Case Rep"},{"issue":"8","key":"10.1016\/j.det.2024.09.001_bib35","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jdcr.2019.03.019","article-title":"Alopecia areata in 2 patients treated with dupilumab: new onset and worsening","volume":"5","author":"Chung","year":"2019","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.det.2024.09.001_bib36","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jdcr.2021.07.015","article-title":"Dupilumab for the treatment of alopecia areata in children with atopic dermatitis","volume":"16","author":"Cho","year":"2021","journal-title":"JAAD Case Rep"},{"issue":"6","key":"10.1016\/j.det.2024.09.001_bib37","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.jaad.2021.01.046","article-title":"Dupilumab therapy for alopecia areata in pediatric patients with concomitant atopic dermatitis","volume":"84","author":"McKenzie","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.09.001_bib38","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/all.15071","article-title":"Phase 2a randomized clinical trial of dupilumab (anti-IL-4R\u03b1) for alopecia areata patients","volume":"77","author":"Guttman-Yassky","year":"2022","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.det.2024.09.001_bib39","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.0105-2896.2009.00867.x","article-title":"Signaling and ligand interaction of ILT7: receptor-mediated regulatory mechanisms for plasmacytoid dendritic cells","volume":"234","author":"Cao","year":"2010","journal-title":"Immunol Rev"},{"issue":"595","key":"10.1016\/j.det.2024.09.001_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf8442","article-title":"VIB7734 Trial Investigators. Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus","volume":"13","author":"Karnell","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.det.2024.09.001_bib41","unstructured":"Study of DAXDILIMAB for the treatment of moderate-to-severe alopecia areata. clinicaltrials.gov [Internet]. Bethesda (MD): National library of medicine. Available at: clinicaltrials.gov\/study\/NTC05368103. (Accessed 3 October 2024)."},{"issue":"37","key":"10.1016\/j.det.2024.09.001_bib42","doi-asserted-by":"crossref","first-page":"22338","DOI":"10.1074\/jbc.M115.661074","article-title":"Targeting the binding interface on a shared receptor subunit of a cytokine family enables the inhibition of multiple member cytokines with selectable target spectrum","volume":"290","author":"Nata","year":"2015","journal-title":"J\u00a0Biol Chem"},{"issue":"2","key":"10.1016\/j.det.2024.09.001_bib43","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/jcph.1522","article-title":"Results from a first-in-human study of bnz-1, a selective multicytokine inhibitor targeting members of the common gamma (\u03b3c) family of cytokines","volume":"60","author":"Frohna","year":"2020","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.det.2024.09.001_bib44","unstructured":"Study of EQ101 in adult subjects with moderate to severe alopecia areata. clinicaltrials.gov [Internet]. Bethesda (MD): National library of medicine. Available at: clinicaltrials.gov\/study\/NTC05589610. (Accessed 3 October 2024)."},{"issue":"2","key":"10.1016\/j.det.2024.09.001_bib45","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40265-024-01997-7","article-title":"Etrasimod: first approval","volume":"84","author":"Shirley","year":"2024","journal-title":"Drugs"},{"issue":"10383","key":"10.1016\/j.det.2024.09.001_bib46","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.det.2024.09.001_bib47","unstructured":"Safety and efficacy of oral etrasimod in adult participants with moderate-to-severe alopecia areata. clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine. Available at: clinicaltrials.gov\/study\/NTC04556734. (Accessed 3 October 2024)."},{"issue":"24","key":"10.1016\/j.det.2024.09.001_bib48","doi-asserted-by":"crossref","first-page":"e126054","DOI":"10.1172\/jci.insight.126054","article-title":"Immunomodulatory activity of humanized anti-IL-7R monoclonal antibody RN168 in subjects with type 1 diabetes","volume":"4","author":"Herold","year":"2019","journal-title":"JCI Insight"},{"issue":"14","key":"10.1016\/j.det.2024.09.001_bib49","doi-asserted-by":"crossref","first-page":"eabd1866","DOI":"10.1126\/sciadv.abd1866","article-title":"Blockade of IL-7 signaling suppresses inflammatory responses and reverses alopecia areata in C3H\/HeJ mice","volume":"7","author":"Dai","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.det.2024.09.001_bib50","unstructured":"Randomized, double-blind, placebo-controlled phase 2a, proof-of-concept trial of ADX-914 phase 2a trial for the treatment of severe alopecia areata (SIGNAL-AA). clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine. Available at: clinicaltrials.gov\/study\/NTC06018428. (Accessed 3 October 2024)."},{"key":"10.1016\/j.det.2024.09.001_bib51","doi-asserted-by":"crossref","unstructured":"Cevikbas F, Rouill\u00e9 T, Barbosa S, et al, A novel human disease model of alopecia areata to evaluate benefit of the DHODH inhibitor farudodstat. Poster presented at: American Academy of Dermatology Annual Meeting; 2024 March 8-12, San Diego, CA.","DOI":"10.1016\/j.jaad.2024.07.048"},{"key":"10.1016\/j.det.2024.09.001_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.718863","article-title":"Mitochondrial-linked De Novo pyrimidine biosynthesis dictates human t-cell proliferation but not expression of effector molecules","volume":"12","author":"Peeters","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.det.2024.09.001_bib53","unstructured":"Investigate the efficacy and safety of farudodstat compared with its placebo in adult alopecia areata participants (FAST-AA). clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine. Available at: clinicaltrials.gov\/study\/NTC05865041. (Accessed 3 October 2024)."},{"key":"10.1016\/j.det.2024.09.001_bib54","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1749-6632.2010.05919.x","article-title":"The role of the PD-1 pathway in autoimmunity and peripheral tolerance","volume":"1217","author":"Fife","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.det.2024.09.001_bib55","unstructured":"A study to evaluate the efficacy and safety of rosnilimab (ANB030) in Treatment of subjects with moderate-to-severe alopecia areata (AZURE). clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine. Available at: clinicaltrials.gov\/study\/NTC05205070. (Accessed 3 October 2024)."},{"key":"10.1016\/j.det.2024.09.001_bib56","doi-asserted-by":"crossref","first-page":"100103","DOI":"10.1016\/j.jtauto.2021.100103","article-title":"NKTR-358: a novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases","volume":"4","author":"Dixit","year":"2021","journal-title":"J\u00a0Transl Autoimmun"},{"key":"10.1016\/j.det.2024.09.001_bib57","unstructured":"A phase 2b study to evaluate rezpegaldesleukin (Rezpeg) in the treatment of severe to very severe alopecia areata in adult patients (Rezolve AA). clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine. Available at: clinicaltrials.gov\/study\/NTC06340360. (Accessed 3 October 2024)."},{"issue":"4","key":"10.1016\/j.det.2024.09.001_bib58","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jid.2022.11.009","article-title":"Diverse role of OX40 on T cells as a therapeutic target for skin diseases","volume":"143","author":"Iriki","year":"2023","journal-title":"J\u00a0Invest Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.09.001_bib59","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/bjd\/ljad240","article-title":"Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial","volume":"189","author":"Weidinger","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2024.09.001_bib60","unstructured":"A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in adult participants with severe alopecia areata. clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine. Available at: clinicaltrials.gov\/study\/NTC06444451. (Accessed 3 October 2024)."},{"issue":"5","key":"10.1016\/j.det.2024.09.001_bib61","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1046\/j.1523-1747.2003.12147.x","article-title":"Hair-cycle-dependent expression of parathyroid hormone-related protein and its type I receptor: evidence for regulation at the anagen to catagen transition","volume":"120","author":"Cho","year":"2003","journal-title":"J\u00a0Invest Dermatol"},{"issue":"12","key":"10.1016\/j.det.2024.09.001_bib62","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/exd.12504","article-title":"Parathyroid hormone-related peptide and the hair cycle - is it the agonists or the antagonists that cause hair growth?","volume":"23","author":"Gensure","year":"2014","journal-title":"Exp Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.09.001_bib63","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/jidsymp.2015.32","article-title":"Therapy for alopecia areata in mice by stimulating the hair cycle with parathyroid hormone agonists linked to a collagen-binding domain","volume":"17","author":"Katikaneni","year":"2015","journal-title":"J\u00a0Investig Dermatol Symp Proc"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073386352400086X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073386352400086X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T13:03:35Z","timestamp":1755695015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073386352400086X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S073386352400086X"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2024.09.001","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovation in Alopecia Areata","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2024.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}